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Sam F. Halabi*
Tim Richard**

ABSTRACT
Although the movement for patient empowerment has been under way for decades,
patients remain relatively marginalized by medical providers, innovators, and payers. Physicians diagnose and prescribe treatment, innovators endeavor to develop
drugs and devices that they can recommend to both physicians and payers, including Medicare. Patients remain in the background, presumed to be passive recipients
of breakthroughs that follow this system of discovery and finance. The law is a
significant reason why this is so. This Article outlines the most significant areas of
law that need to change to allow patients to innovate in collaborative partnership
with their physicians, including the law of tort, human subjects research, healthcare
finance, and intellectual property. By identifying these areas, changes and modifications to law may be more easily assessed by both state and federal law-makers.
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I. INTRODUCTION
Despite a decades-long movement nominally committed to patient autonomy,
informed consent, and sovereignty, the actual position of the patient in the modern
U.S. healthcare system remains largely that of a passive recipient of the advice of
providers (generally physicians) and the drugs and devices of biomedical developers and manufacturers.1 Although researchers have developed measures of patient
engagement and patient activation, the average patient follows up on referrals to
specialists, fills and manages medications, and complies with physical therapy and
other regimes provided by others.2
To some extent, this dynamic results from the knowledge disparities between
patients on the one hand and, on the other, providers and innovators. Physicians are
extensively trained, and patients may be easily misled by poor information, or misunderstand valid information.
Online health information is difficult to regulate, meaning quality control is a
challenge, and, further, patients vary widely in their health information literacy. Bad
health information used in an improper way can be highly detrimental. Patients
might trust misleading information or might make important health decisions based
on sensationalized or emotionally charged stories that are not relevant to their health
context.3
Yet patients also have a tremendous amount of knowledge about their own
conditions and many of them are well-equipped to help adapt and innovate treatments. Their incentives are almost always aligned with outcomes.4 Patients want to
heal and they want to invest in what they need to do so.5 This is particularly true for
patients with complex, rare, or unknown diagnoses.6
Consider the case of Doug Lindsay. Doug suffered from debilitating and degenerative chronic fatigue. Related maladies ran through his family history, but
there was never an effective diagnosis or treatment.7 After consulting a 2,200-page
* Manley O. Hudson Professor of Law, the University of Missouri-Columbia; J.D., Harvard Law School;
MPhil, University of Oxford (St. Antony’s College); B.A., B.S., Kansas State University.
**J.D. Candidate, University of Missouri School of Law.
1.Barbara Chubak, Clinical Responsibility in the Age of Patient Autonomy, 11(8) VIRTUAL MENTOR 567,
Aug. 2009, at 567. (“The Principles of Biomedical Ethics by Thomas Beauchamp and James Childress,
arguably the foundational text of contemporary bioethics, was first published in 1979 at the close of a
decade that witnessed the rise of the international patients’ rights movement. In the United States, this
movement placed, and continues to place, a particular emphasis on individual choice, in keeping with
the dominant political ethos of our nation, which since its conception has privileged the enlightened,
rational, and productive individual actor. Out of these ideas, the principle of respect for autonomy was
born, and, since then, the influence of this single principle on the provision of health care and conduct
of biomedical research has eclipsed that of the other principles: beneficence, nonmaleficence, and justice.”).
2. Len Schlesinger & John Fox, Giving Patients an Active Role in Their Health Care, HARV. BUS.
REV., Nov. 21, 2016.
3. Tabitha Tonsaker, MSc, Gillian Bartlett, PhD, & Cvetan Trpkov, Health information on the Internet: Gold mine or minefield?, 60(5) CANADIAN FAM. PHYSICIAN 407, May 2014, at 407.
4. https://healthpayerintelligence.com/news/patient-incentives-from-payers-encourage-preventivecare-visits
5. Harold DeMonaco, Pedro Oliveira, Andrew Torrance, Christiana von Hippel, & Eric von Hippel,
When Patients Become Innovators, MIT SLOAN MGMT. REV., Feb. 21, 2019.
6. Id.
7. Ryan Prior, This College Dropout was Bedridden for 11 Years. Then he Invented a Surgery and
Cured Himself, CNN (July 27, 2019, 11:40 AM), https://www.cnn.com/2019/07/27/health/doug-lindsayinvented-surgery-trnd/index.html.
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endocrinology textbook he happened upon, he reasoned that his illness may be related to adrenal glands on his kidneys.8 After additional research, he refined his
diagnosis to an autonomic nervous-system disorder.9 Lindsay presented his findings
to a conference held by the National Dysautonomic Research Foundation, a charity
committed to the condition he suffered.10 Lindsay’s disorder was almost unheard
of, and most researchers in attendance had determined this diagnosis was highly
improbable. While at the conference, Lindsay met Dr. H. Cecil Coghlan, a medical
professor at the University of Alabama-Birmingham who believed Lindsay had proposed a valid theory. Dr. Coghlan helped Lindsay repurpose a drug approved for an
entirely different condition, and then helped Lindsay research and pioneer a surgery
for his condition. Prior to surgery, Lindsay could sit for no more than an hour or
two a day.11 Within two months of the surgery, he was able to walk a mile to church
and went on a major vacation six months after that. 12 Had Lindsay not innovated
with respect to both medicine and surgery, he would not have found a cure. Doctors
had been unable to figure out what was going on with his body, and his situation
was rare enough that there was no market to justify pharmaceutical company investment.
While Lindsay’s story is multifaceted – involving physicians, non-profit organizations committed to medical research, market failures for rare diseases, and more
– this essay focuses on the law. Specifically, at which points in the patient innovation process does law facilitate or hinder treatments, medicines, devices, and/or surgeries that a patient has determined, in consultation with providers, to be in her best
interest, but deviates from the standard of care? Closely related, how does law affect
the decisions of payers, primarily insurance companies, to manage situations in
which well-informed patients challenge standard practice, sometimes in ways that
are less expensive?

II. THE STANDARD OF CARE, HUMAN SUBJECTS RESEARCH, AND
EXCEPTIONS FOR CLINICAL INNOVATION
Even when patients come to their providers with ideas and innovations as to
medications, devices, and treatment regimens, providers remain constrained by the
standard of care of like physicians who treat the same ailment or condition. 13 Innovation is by definition the pioneering of new treatment options.14 The inherent conflict is clear: when a provider aids a patient or implements the patient’s innovative
approach, she deviates from the standard of care. The resulting conflict is one between pushing new understandings of medicine to better treat patients and risking
vulnerable patients on unproven or unknown procedures. Thus, there is a need for
governance of the relationship to ensure that providers do not face excess liability
8. Id.
9. Id.
10. Id.
11. Id.
12. Id.
13. See Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (1978). There are some modifications depending on local law. Some physicians are further held to the standard of physicians in that
community. In most cases, the standard of care is also shaped by available resources like technology,
staffing, and nearby tertiary care centers.
14. Innovation, DICTIONARY.COM, https://www.dictionary.com/browse/innovation?s=t (last visited
Nov. 23, 2020).
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and patients are adequately informed as to the standard of care and the risks that
accompany the deviation and innovation.15
For innovations so described, they are considered “research,” not medical practice, and the protections that humans enjoy when they are medical research subjects
are extensive. Medical practice is defined by the Belmont Report16 as “interventions
which are designed solely to enhance the well-being of an individual.”17 “Research”
is defined as activity designed to test a hypothesis and thereby contribute to general
knowledge.18 “Innovation” (other than research) is a significant departure from
standard practices, but not necessarily subject to rigorous review for purposes of
testing a hypothesis.19
These distinctions are critical when discussing surgical innovation, especially.
Surgeons frequently deviate from standard practices with each patient, as each is
unique and requires the surgeon to tailor each operation.20 The law thus becomes
amorphous and ill-defined at the boundary at which a surgeon is innovating or
merely tailoring the surgery.
Research generally lends itself to a rigorous process of approval and verification, primarily to ensure that risks are balanced with benefits for human medical
research subjects, and that the subjects are adequately informed of those risks.
When attempting to add to the general knowledge of medicine, providers must be
careful to take the proper steps and draw the correct conclusions. 21 The Belmont
Report is clear that an evaluation of efficacy or safety falls within the realm of research.22
Patient innovation therefore lies between the legal protection of medical malpractice tort liability and the protections offered (importantly by federal law as well
as state) for human research subjects. 23 The malpractice pathway is one in which
the provider is subject to minimal scrutiny while performing the innovative treatment, but afterwards may be held liable in any malpractice suits that may be brought
in tort.24 The human subjects research pathway is a more prospective approach, requiring a greater degree of oversight and regulation, but minimizing liability for the
doctor afterwards.25
The medical practice pathway, from a legal standpoint, is a natural extension
of basic tort and medical malpractice law. The patient needs the provider to undertake the innovation, but the provider (and certainly its insurer) may be deterred by
15. See Anna C. Mastroianni, Liability, Regulation, and Policy in Surgical Innovation: The Cutting
edge of Research and Therapy, 16 HEALTH MATRIX 351, 354 (2006).
16. See generally NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN SUBJECTS OF
BIOMEDICAL AND BEHAVIORAL RESEARCH, DHEW Pub. No. (OS) 78-0012, THE BELMONT REPORT:
ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH 11
(1978).
17. Nancy M.P. King, The Line Between Clinical Innovation and Human Experimentation, 32 SETON
HALL L. REV. 573, 573 (2002) (citing NATIONAL COMMISSION FOR THE PROTECTION OF HUMAN
SUBJECTS OF BIOMEDICAL AND BEHAVIORAL RESEARCH, DHEW Pub. No. (OS) 78-0012, THE
BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS
OF RESEARCH 11 (1978).
18. Id.
19. Mastroianni, supra note 13, at 361.
20. Id. at 364.
21. See Id. at 358-59.
22. Id. at 361.
23. Id. at 370-71.
24. Id.
25. Id.

https://scholarship.law.missouri.edu/betr/vol4/iss2/4

4

Halabi and Richard: The Law of Patient Innovation

No. 2]

Halabi : The Law of Patient Innovation

249

tort liability.26 A patient whose innovation has failed and results in real or perceived
injuries will not only have the basic elements of a tort claim satisfied, but will inevitably have experts who will testify that the innovated procedure or treatment did
not meet the standard of care.27 In some cases, an innovative surgery may fall outside what is considered the customary practice; however, in other cases, courts appear to give great deference to defendant-physicians in exercising their best judgement.28 Indeed, some courts recognize therapeutic innovation as a defense, carving
out protections for physicians who make themselves knowledgeable about treatment alternatives and work with patients to innovate in ways that promote patient
welfare but do not arise to experimentation.29
Alternatively, patient innovation may be advanced as research. Within the research framework, the innovation process is necessarily researcher led, with specific rules that weigh risks to patients and ensure that they are effectively and comprehensively informed.30 The patient is made aware of all risks and benefits of the
treatment, and sometimes even the physician is forced to re-examine their thinking
and justifications for a procedure.31 Informed consent adds an ethical layer of patient protection to the legal one. 32 The process is overseen by an Institutional Review Board (“IRB”) or ethics committee, which is charged with approving the research protocol and monitoring patient benefits and risks over the course of the
study.33
Yet by its nature, the federally guided research process marginalizes patients.
Patients are not generally interested in research design that contributes to
knowledge, including requirements for double-blind clinical trials. They are interested in innovations that will promote their own health and lives.34
Even the ethical criteria of patient research are tilted against patient-led innovation.35 While an operation or procedure may pose risks desperate patients are
willing to ignore at their peril, these same risks are weighed by Institutional Review
Boards and ethics committees, who may give decisive weight to the benefits of not
treating the patient, or not innovating.36
Physicians are constrained legally by a potential for severe liability in the face
of malpractice suits.37 Federal regulations guiding informed consent cabin the patient into a passive role.38 The informed consent process allows the patient to take
an active role in the process only by permitting or prohibiting the innovative
26. Id. at 376.
27. Id. at 377
28. See Brook v. St. John’s Hickey Mem’l Hosp., 380 N.E.2d 72, 76 (1978) (holding that a physician
injecting a contrast medium into the calves of a child instead of the standard gluteal muscle site was not
a breach, as the physician adjudged it the prudent course after reading journal articles about injuries from
injecting contrast medium in the wrong places).
29. Mastroianni, supra, note 13, at 380-81.
30. Id.
31. Id. at 416-18
32. See King, supra note 15, at 578.
33. 45 C.F.R. § 45.111 (2020); 21. C.F.R. § 56.111 (2020).
34. Mary E. Tinetti & Ethan Basch, Patients’ Responsibility to Participate in Decision Making and
Research, 309(22) JAMA 2331, 2331 (2013).
35. King, supra note 15, at 573.
36. Id.at 581.
37. Alberto Galasso & Hong Luo, Physicians liability and medical innovation, VOX EU CEPR,(July
24 2016), https://voxeu.org/article/physician-liability-and-medical-innovation.
38. See Benjamin Littenberg & Charles D. MacLean, Passive Consent for Clinical Research in the
Age of HIPPA, 21(3) J. OF GEN. INTERNAL MED. 207, 211 (2016).
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treatment solution offered by the physician.39 In short, patients have the final say in
whether a treatment happens, and when a physician circumvents the patient’s approval, some courts have held the physician liable for battery. 40

III. THE LAW OF HEALTHCARE PAYMENT
Even if a patient succeeds in convincing his or her physician that the risk of
malpractice liability is negligible and decides to proceed outside the federally-regulated research process, who is to pay for potentially expensive innovations developed by patients?41 Insurance companies, the Centers for Medicare and Medicaid
Services, and even charitable organizations typically make decisions as to whether
to cover treatment based on proven safety, efficacy, and standard practice. 42
While patient innovation is driven by the unique resources of personal experience and dedication to life improvement, payers are able to utilize massive amounts
of data regarding their customers (those same patients). 43 Payers have significantly
more information about the long-term effects of drugs and are able to push for innovation in light of that information. One such example was the removal of Vioxx
from the market after Kaiser Permanente, a large integrated provider and payer, was
able to demonstrate the drug caused fatal heart attacks.44 Vioxx was a new generation of pain medication developed by Merck. The drug obtained FDA approval. 45
However, years later, Kaiser Permanente undertook a study to compare patients
who took the drug with those who had not and found that those who took it were
significantly more likely to experience a heart attack.46 Kaiser Permanente could do
this because of its considerable access to patient information. The information available to Kaiser was much larger in scope than that of Merck’s lab studies. After the
results of the data were published, Vioxx was pulled from the market, and its risks
were eliminated.47
This story demonstrates that innovation for payers does not come in the form
of any sort of physical good (i.e., the artificial pancreas or a new pain medication),
but rather in the form of information.48 Payers are able to learn more about
healthcare, as opposed to providing a physical, tangible innovation.49
As a result, the current incentives for medical innovation (patents and exclusivity) are generally not conducive to payer data innovation.50 In the absence of a
new good to sell, payers keep secret the information they learn regarding health care
39. Mastroianni, supra note 13, at 416-18.
40. Id. at 417.
41. Sonali R. Mishra et al., “Not Just a Receiver”: Understanding Patient Behavior in the Hospital
Environment, PROCEEDINGS OF THE SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING
SYSTEMS. CHI CONFERENCE, 3103–3114 (May 2016), https://doi.org/10.1145/2858036.2858167 (“During these stays, patients are often viewed as passive recipients of care, rather than as active stakeholders
who can make decisions and even prevent errors.”).
42. See Demonaco et al., supra note 4.
43. Rebecca S. Eisenberg & W. Nicholson Price, Promoting Healthcare Innovation on the Demand
Side, 4(1) J.L.&BIOSCI. 3, 3 (2017).
44. Id. at 8.
45. Id.
46. Id.
47. Id.
48. See Demonaco et al., supra note 4.
49. Eisenberg & Price, supra note 41, at 30.
50. Id. at 12.
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and use what they learn for themselves to cut costs and increase profit where possible.51 Therefore, a patient who innovates as to treatment must not only prove its
effectiveness, but also its cost efficiency, for purposes of most payer interests. The
motivations payers have to innovate can be similar to, but may differ from, patients.
While patients are seeking relief from disorders or symptoms, often payers are seeking to minimize costs in healthcare.52 Payers usually target innovation that can reduce cost either by remaking a drug from prescription-only to over-the-counter, or
by demonstrating that a newer and more expensive drug is not necessary compared
to a cheaper, older drug.53 This sort of cost minimizing is only available to payers,
as the other major actors in the healthcare system either are missing the resources
or incentives to do so.54 The drug manufacturers and providers both seek a profit,
and the patient has minimal access to the larger data necessary to drive the innovation payers are able to create.55
However, some advocates for patient innovation claim a comparative analysis
of risk is possible. Demonaco argues the risks taken on by patients using homemade devices and treatments should be compared to the risks a patient faces if not
using any device at all. 56 When this paradigm is used, the benefits offered by a
device may outweigh the risks it involves. Often, payers are willing to share their
information with physicians, who may use it in some circumstances to aid patient
innovations.57
Payer innovation in aid of patient innovation may also advantage physicians.
One such example is off-label prescription, or when a drug is used for something
other than what it was produced and tested for by the manufacturer. 58 Drug manufacturers have little to no incentive to undertake expensive trials for the efficacy of
drugs in off-label uses.59 Payers can fill a vital role here by supporting the doctor’s
off-label uses as a means for treatment and verifying its effectiveness with largescale data. Because a payer is the only one with access to broad spectrum data regarding treatment practices of patients, they are able to confirm an off-label use as
effective or not and have an incentive to do so.60
Doctors, then, are exercising a healthy and justified skepticism regarding patient innovation. A homemade remedy or device can be incredibly risky for the patient. Additionally, a patient offering an opinion on their treatment in the face of a
doctor’s expertise is, at the least, unhelpful. In the rare instance that a patient can
research sufficiently as to discuss with confidence their own ailments and potential
treatments, doctors still act with trepidation upon a patient’s recommendations. 61
Payers present a slightly different story in that they are equipped with patient data

51. Id.
52. Id.
53. Id.
54. Id.
55. Id.
56. See Demonaco et al., supra note 4.
57. Eisenberg & Price, supra note 41, at 30.
58. Sam F. Halabi, Off-Label Marketing’s Audiences: The 21st Century Cures Act and the Relaxation
of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims, 44 AMERICAN JOURNAL
OF LAW & MEDICINE 181 (2018).
59. Id.at 18.
60. Id. at 19.
61. Rebecca E. Say &Richard Thomson, The Importance of Patient Preferences in Treatment Decisions–Challenges for Doctors, 327 BMJ 542, 544 (2003).
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exceeding that of providers or even drug testing by manufacturers. 62 While often
the interests of providers and payers collide, much can be accomplished when the
two are able to cooperate.63
Relatively little writing or literature is available regarding the attitude an insurance company may have towards, say, Doug Lindsay’s situation. After all, it would
be a hard pitch to an insurance company to get them to greenlight a surgery created
by their customer. However, Eisenberg talks at length about the primary motivation
of payer innovation: profit.64 It is perfectly reasonable to assume, then, that an insurance company may be at least interested in covering the cost of cheaper and more
effective treatments, despite them being created by the patient. For example, in
Lindsay’s situation, the two choices are to continue a lifetime of high-cost care, in
and out of hospitals and paying for expensive treatments that doctors are uncertain
about; or paying for one surgery that Doug has prepared a lengthy treatise to demonstrate the possibility of a cure. With the success of Lindsay’s surgery came an elimination of costly treatments, so it appears logical the payer would support these innovations where it can. Another example is the artificial pancreas, as discussed by
Demonaco.65 A combination of a basic insulin pump and a cheap ($30) computer
can create a more effective treatment than the constant use of disposable test kits
and costly doctor’s appointments.66 So, considering the profit incentive, it makes
sense for a payer in many situations to financially support patient innovation in
some measure.
The patient innovator has several complicated motivations, ranging from solving their own ailments, to helping others do the same, to potentially making a marketable product. The payer is interested in profit.67 Payers innovate where profit
intersects with new knowledge. For example, Blue Cross worked to get a non-sedative antihistamine approved as an over-the-counter (OTC) medication instead of
one requiring a prescription.68 The manufacturers of the non-sedative antihistamine
were resistant to change the drug to OTC, so as to maximize the amount of time
they had the exclusive right to sell the drug. However, Blue Cross California
demonstrated that the non-sedative was just as safe if not safer than standard (sedating) antihistamines, and thus should be approved as an over-the-counter alternative.69
The other side of this coin is the efficiency check payers offer on the system. 70
Often, manufacturers and providers are creating newer and more elaborate forms of
treatment (new drugs, devices, procedures, and methods) that cost more, and may
or may not be more effective than the previous treatments. The payer offers a check
on this by working to determine what is the most efficient method of treatment. One
example is payer research into precision medicine.71 This is a form of treatment
62. Jeff Lagasse, Better Data Sharing Between Payers, Providers Can Move the Needle on Social
Determinants of Health, (Mar. 24, 2020), https://www.healthcarefinancenews.com/news/better-datasharing-between-patients-providers-can-move-needle-social-determinants-health.
63. See Id.
64. Eisenberg & Price, supra note 41, at 5.
65. See Demonaco et al., supra note 4.
66. Id.
67. Eisenberg & Price, supra note 41.
68. Id. at 8.
69. Id.
70. Id. at 18.
71. Id. at 21.
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where a genetic test is taken of a patient to identify what drugs would be the most
effective in the patient due to their genetic makeup.72 The resulting treatment is able
to specifically target those who would benefit from a preventative drug (such as
Herceptin, used to prevent breast cancer).73 This interests large drug manufacturers
less because they are interested in ensuring as many people purchase and consume
their drug as possible. But it aligns neatly with what payers want, to ensure only
those who need treatment are getting it. This forced efficiency acts as a check on
the drug makers in a way that benefits patients as well as payers.
The primary resource payers are utilizing for innovation is their data. 74 Many
payers do not have their own drug researchers or clinical lab studies, but they have
access to all the healthcare information of their clients. From doctor visits to prescriptions to diagnoses, payers know a great deal about those for whom they issue
payments This offers them an opportunity that drug manufacturers and even providers do not have. With a large-scale and long-term view of all of their patients,
payers are much more able to recognize trends that others may not. A manufacturer
may not understand the long-term effects of its drug, especially when those effects
materialize outside the time of a clinical study. A provider may not realize their
patient is seeing another doctor for something that seems unrelated but can tie into
their work (such as patients prescribed Vioxx seeking a cardiologist). And a patient
has no way of knowing their experience is part of a larger trend. The only one who
can really step into this place is the payer who is seeking to reduce their costs by
implementing new standards based on the large-scale data they have.
Another hurdle is the data itself. The reality is that perfect data about imperfect
humans is very difficult, if not impossible, to collect. There are a myriad of problems encountered in the data.75 First, patients change payers over their lives. A payer
does not always have life-long data on one patient, as they move around between
providers.76 Additionally, secrecy (as discussed above)77 and HIPAA dis-incentivizes payers from sharing patient data with patients who might benefit from it.78
There is no standardized format for data of health records, so it can be difficult or
impossible to merge data across payers.79

IV. THE LAW OF DRUG AND DEVICE REGULATION
The U.S. Food and Drug Administration is the most important regulator of
drugs and devices relevant to patient innovation.80 As the authority on guidelines
and safe practices, compliance with their standards is necessary to offer innovations
in a commercial setting. This review, approval, and subsequent compliance with
FDA regulations is expensive and often cost-prohibitive for treatments with small
markets.81
72. Id. at 20-21.
73. Id. at 20.
74. Id. at 12.
75. Id. at 23.
76. Id. at 22.
77. See discussion supra Part III.
78. See discussion supra Part III.
79. Eisenberg & Price, supra note 41, at 5.
80. FOOD AND DRUG ADMINISTRATION, FDA AT A GLANCE (October 2019), available at
https://www.fda.gov/media/131874/download.
81. See Demonaco et al., supra note 4.
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Patient innovators circumvent this by avoiding commercialization. 90% of patient innovators offer their designs and inventions for free to the public. 82 Because
these patients are not selling their developments, they do not need to conduct largescale tests of their product, and instead can simply make it and share what they
found works with others in similar situations. 83 Under the commerce clause, the
FDA cannot regulate noncommercial activity.84 Patient innovators are seeking some
form of treatment for their own needs, thus their reward and motivation is not profit,
but rather relief from symptoms or a cure.85
Payers encounter the FDA in more complicated ways. The FDA works closely
with manufacturers to ensure sufficient testing is being performed. Because payers
want to learn more about drugs on the market, the FDA prefers not to be involved.86
The FDA states their “institutional mission is approving new drugs, not re-evaluating already approved drugs.”87 The FDA prefers to rely on clinical studies over
observational studies.88
The FDA encourages drug manufacturers to research off-label uses for their
drugs to assist in off-label innovation.89 The FDA prohibits the active marketing of
off-label uses, but even that assertion has receded in the face of some First Amendment challenges, which have argued that all parties should be able to make truthful,
non-misleading statements about drugs, even off-label uses.90
The FDA has adapted the payer’s model of developing patient records for its
own research purposes, which carries an indirect approval of payer methods. In
what is called the Sentinel Program, the FDA has established a network of patient
records so as to monitor the long-term effects of drugs.91
In sum, the FDA appears to be apathetic at best and resistant at worst toward
patient innovation. Patients who develop their own cures or devices must circumnavigate the FDA by sidestepping the bases of federal jurisdiction. The FDA has
not taken an overtly hostile position towards these patient innovators who stay
within the non-commercial space.92 Payers face both hurdles and assistance from
the FDA: sometimes they are resistant towards re-examining a drug in light of new
evidence, other times they work closely with payers to research the efficacy and
safety of drugs with long-term data, and recently they have begun adapting payer
methods to do research for themselves.

82. Id.
83. Id.
84. Id.
85. Id.
86. Eisenberg & Price, supra note 41, at 9.
87. Id. at 11.
88. https://endpts.com/fda-will-allow-observational-studies-as-part-of-a-push-for-real-world-evidence-new-framework-says/
89. Id. at 18-19.
90. Id. at 19.
91. Id. at 39.
92. Scott Gottlieb, FDA’s Comprehensive Effort to Advance New Innovations: Initiatives to Modernize for Innovation, U.S.FOOD AND DRUG ADMINISTRATION (Aug. 29, 2018),
https://www.fda.gov/news-events/fda-voices/fdas-comprehensive-effort-advance-new-innovations-initiatives-modernize-innovation.
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V. THE LAW OF INTELLECTUAL PROPERTY
Innovations may also be valuable in ways that are sufficient to be protected by
patents, copyrights, or trademarks.93 Given the potential financial interests, a conflict of interest may develop between the patient and the provider as to who “owns”
all or most aspects of the innovation. While surgical processes are notoriously difficult to protect with intellectual property mechanisms, devices may in fact be very
valuable, especially some that patients have developed like those relevant to physical therapy.94
In the well-known case of Moore v. The Regents of the University of California,
a patient sued the doctor who treated him for hairy-cell leukemia, challenging the
physician’s orders to remove his spleen as well as “blood, bone marrow aspirate,
and other bodily substances,” The patient alleged that the physician’s intent to use
those substances in potentially lucrative clinical research conflicted with the patient’s interest in the best health outcome.95 The Supreme Court of California determined that the physician had breached his fiduciary duty, not of loyalty, but of
disclosure, since the economic interest of a physician may be material to a patient’s
decision. 96
[A] physician who is seeking a patient’s consent for a medical procedure must,
in order to satisfy his fiduciary duty and to obtain the patient’s informed consent,
disclose personal interests unrelated to the patient’s health, whether research or economic, that may affect his medical judgment.97
In that decision, the court adopted the “reasonable patient” standard when determining materiality. 98 Most courts have adopted a “reasonable physician” inquiry
that operates much like a standard of care analysis privileging physicians’ opinions
of one another, not the trust relationship they share with the patient. 99
Several courts have held that physicians have an affirmative duty to disclose
information that will affect a patient’s care. 100 For instance, physicians have an
affirmative duty to disclose to patients any financial interest in clinical research.101
What happens when a patient comes to the physician with a potentially lucrative

93. Joshua A. Vecht, ET AL.,Surgeons produce innovative ideas which are frequently in the labyrinth
of patents, 35 EUR J.CARDIOTHORAC SURG. 400, 400(2009).
94. Jonas Anderson, Nonexcludable Surgical Method Patents, 61, WM. & MARY L. REV.637, 676
(2020).
95. Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 481 (Cal. 1990).
96. Id. at 485.
97. Id.
98. Nadia Sawicki, The Abortion Informed Consent Debate: More Light, Less Heat, 21 CORNELL J.L.
PUB. POL’Y 1, 19 (2011); Nixdorf v. Hicken, 612 P.2d 348, 354 (Utah 1980) (“The relationship between
a doctor and his patient creates a duty in the physician to disclose to his patient any material information
concerning the patient’s physical condition. This duty to inform stems from the fiduciary nature of the
relationship . . . .”).
99. 5 Med. Malpractice (Matthew Bender) § 22.05 (2013) (reporting that the reasonable patient standard “remains the minority position”). In states using the reasonable physician standard, a physician would
only be required to disclose “an interest extraneous to the patient’s health” if other physicians customarily did so. Moore, 793 P.2d at 484.
100. Emmett v. Eastern Dispensary and Casualty Hosp., 396 F.2d 931, 935 (D.C. Cir. 1967) (“We find
in the fiducial qualities of that relationship (between physician and patient) the physician’s duty to reveal
to the patient that which in his best interests it is important that he should know.”).
101. Marc. A Rodwin, Strains in the Fiduciary Metaphor: Divided Physician Loyalties and Obligations
in a Changing Health Care System, 21 AM. J. L. & MED. 241, 248 (2005).
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idea? How might patient interest in healing and physician interest in a patent compromise the patient innovation possibilities?
Indeed, by choosing to seek out and desire medicine labeled “cutting edge” and
innovative, patients drive demand for those who innovate and may be interested in
such incentives.102 Surgeons in particular are driven by prestige and economic demand to innovate. It is not just patients who drive this demand. The best hospitals
want pioneering surgeons, media attention is given to those who can make a breakthrough, and academic communities give prestige to innovative surgeons. 103 All of
this acts as a drive for surgeons to be the next pioneer, and at the forefront of that is
the patient who demands a new treatment for their ailment. Should patients decide
they no longer desire innovative surgeries, there would be little financial incentive
for surgeons and providers to continue pushing new bounds. While the raw demand
for an innovative procedure results in providers willing to do so, the flip side is the
risk the patient offers as a potential liability for the provider.104 When a new procedure becomes available, there is a lifecycle of malpractice suits that arise, driving
physicians to perfect and stabilize the procedures and make patients safer. 105

VI. SOLUTIONS
Ultimately, there is a balance that must be sought among the competing legal
interests outlined above: innovating and advancing human understanding of medicine, while maintaining the safety and agency of patients. This balance is what the
federal Belmont Report sought, as well as subsequent federal regulations on innovation.106 The current attitude by legal scholars appears to be a desire to increase
oversight and place more restrictions on innovation.107 Recommendations center
around increasing oversight through registries and standardizing decision-making
for physicians. The benefits are obvious, fewer rogue physicians means fewer injuries. But the downsides to restricting innovation to established standards of care or
expensive formalized research are important to consider as well.
One solution may be expanding what is considered the standard of care. If we
simply consider the standard of care to be what other doctors in the same situation
do, then we will see only incremental improvements, as the common law contemplates.108 However, if we expand the standard of care to both allow for innovation
and require adherence to certain guidelines, it is a promising middle ground.
Some jurisdictions are already doing this. In Henrich v. Sweet, the 1st Circuit
indicated having a procedure reviewed by an Institutional Review Board before implementing it upon a patient may serve as a partial defense to malpractice claims.109
This allows for a patient and her doctor to practice somewhat outside standards of
practice, but only at the approval of neutral observers who may adjudge the risks
102. Mastroianni, supra note 13, at 363-364.
103. Id.
104. See generally Id. at 374 (speaking on medical practice pathway to legal oversight).
105. Id. at 374-75 (quoting Kenneth A. De Ville, Medical Malpractice in Twentieth Century United
States: The Interaction of Technology, Law and Culture, 14 INT’L J. TECH. ASSESSMENT HEALTH CARE
197, 204 (1998)).
106. See generally King, supra note 15, at 573-582.
107. Mastroianni, supra note 13, at 433; King, supra note 15, at 581.
108. Charles P. Sabatino, The Evolution of Health Care Advance Planning Law and Policy, 88 THE
MILBANK Q. 211, 218 (2010).
109. Heinrich v. Sweet, 308 F.3d 48, 69 (1st Cir. 2002).
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and benefits better than the doctor or the patient. By expanding the standard of care
to not simply cover the actions of the doctor immediately surrounding the treatment
of the patient, but rather including how they go about seeking professional review,
it may be possible to limit the risks of rogue treatment while also allowing doctors
to innovate in a streamlined manner.
Establishing a standard of care that requires doctors to submit to oversight from
Institutional Review Boards or federal guidelines, and patients to give informed
consent can result in patients being treated safely and doctors being able to innovate
and pioneer new treatment. Doug Lindsay’s story has what appears to be a typical
demonstration of a doctor’s attitude to patient innovation. Many of the doctors Doug
met with were skeptical of his theories and proposed treatment plans.110 This comes
with good reason, too. Often, patients know little beyond what their body tells them.
“I’m chronically exhausted” can be the symptom of a wide array of symptoms, and
it seems unreasonable that a patient should have much say in diagnosis theorizing
as the individual with years of training and experience in this subject. It took Doug
attending the conference of Dysautonomic Researchers with years of his own research into this narrow topic before even one person at the conference listened to
him.111 Later, when he designed a surgery, he prepared over 300 pages of research,
plans, and evidence of the efficacy of this surgery, and he still had to pitch it to
many, many surgeons before one of them agreed to perform it. 112 The risks faced
by surgeons who agree to perform unproven surgeries can include financial loss in
the form of malpractice suits and loss of their license. 113
Payers could open up more channels to receive innovative and cost-effective
ideas from patients. Many have some limited forums for patient feedback; most
have some sort of technological review for recently approved or contemplated drugs
and devices. These arms of insurance companies could be expanded and some of
their own research resources dedicated to mining their own data to confirm experimental hypotheses. The information could be published for patients to consult with
their physicians.
With respect to intellectual property, the problems are more difficult to solve,
but they may be rarer. Use of medications off-label is likely to mean that they are
no longer protected by patents in any case.114 Surgical methods are already difficult
or impossible to patent.115

VII. CONCLUSION
Patient innovation is an important step in the decades-long movement toward
patient autonomy, agency, and sovereignty. This essay has endeavored to outline
some of the main legal barriers and questions that surround patient innovations, the
physicians, payers, and regulators that surround them. As these innovations

110. Prior, supra note 6.
111. Id.
112. Id.
113. Ronald M. Stewart et al., Trauma Surgery Malpractice Risk: Perception Versus Reality 241(6)
ANN. SURG. 969 (2005).
114. See Sam F. Halabi, The Drug Repurposing Ecosystem: Intellectual Property Incentives, Market
Exclusivity, and the Future of “New” Medicines, 20 YALE J.L.AND TECH.1, 24 (2018).
115. See Anderson, supra note 90, at 637.
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advance with more access by patients to more information, hopefully, it will provide
a useful guide to addressing the many complicated questions that will arise.
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